期刊
MOLECULAR PHARMACOLOGY
卷 96, 期 6, 页码 809-818出版社
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.118.115329
关键词
-
资金
- European Union's Horizon 2020 MSCA Program [641833 ONCORNET]
- European Union's Infect-ERA project HPV-Motiva [ANR-15-IFEC-0004-0]
- PRC ANR Grant OSTEOVALYMPH [17-CE14-0019]
- ANR under the program Investissements d'Avenir [ANR-10-LABX-33, ANR-11-IDEX0003-01]
- Fondation de la Recherche Medicale (FRM)
- Agence Nationale de la Recherche (ANR) [ANR-15-IFEC-0004] Funding Source: Agence Nationale de la Recherche (ANR)
Atypical chemokine receptor 3 (ACKR3), previously known as C-X-C chemokine receptor type 7 (CXCR7), has emerged as a key player in several biologic processes, particularly during development. Its CXCL11 and CXCL12 scavenging activity and atypical signaling properties, together with a new array of other nonchemokine ligands, have established ACKR3 as a main regulator of physiologic processes at steady state and during inflammation. Here, we present a comprehensive review of ACKR3 expression in mammalian tissues in search of a possible connection with the receptor function. Besides the reported roles of ACKR3 during development, we discuss the potential contribution of ACKR3 to the function of the immune system, focusing on the myeloid lineage.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据